Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578365 | 1.00 | TACR1 (0.42) | TACR1RORCHDAC1HDAC2NR1H2 | |
| SCHEMBL30551260 | 0.98 | TACR1 (0.41) | TACR1RORCHDAC1HDAC2NR1H2 | |
| SCHEMBL29343648 | 0.88 | NR1H2 (0.46) | RORCNR1H2NR1H3KMT2AHSD11B1 | |
| SCHEMBL24364913 | 0.88 | NR1H2 (0.45) | TACR1RORCNR1H2NR1H3MEN1 | |
| SCHEMBL29081517 | 0.88 | NR1H2 (0.45) | TACR1RORCNR1H2NR1H3MEN1 | |
| SCHEMBL29081516 | 0.88 | NR1H2 (0.45) | TACR1RORCNR1H2NR1H3MEN1 | |
| SCHEMBL31578439 | 0.85 | TACR1 (0.41) | TACR1RORCHDAC1HDAC2NR1H2 | |
| SCHEMBL25923744 | 0.85 | TACR1 (0.41) | TACR1RORCHDAC1HDAC2NR1H2 | |
| SCHEMBL25322725 | 0.85 | FFAR2 (0.36) | CACNA1H | |
| SCHEMBL25321910 | 0.84 | FFAR2 (0.36) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | TACR1 310/4885RORC 486/4885HDAC1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.